Mainz Biomed N.V. has announced the next phase in its PancAlert project, which aims to develop a non-invasive blood test for early pancreatic cancer detection. Following a successful discovery ...
Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...
Importantly, the algorithm developed by Liquid Biosciences not only distinguished pancreatic cancer from healthy controls but also detected precancerous lesions that have the potential to develop into ...
Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY ...
BERKELEY, US and MAINZ, Germany – December 19, 2024-- Mainz Biomed N.V. MYNZ ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, ...
ReconAAsense study examining the clinical performance of mRNA and DNA test combined with a fecal immunochemical test for early detection of advanced adenoma and colorectal cancer to enroll 15,000 ...
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population 21.01.2025 / 14:01 CET/CEST The issuer is solely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results